W
Weijiexin Biological Technology
Recombinant protein and antibody drugs for veterinary use
About Weijiexin Biological Technology
Beijing Weijiexin Biological Technology Co., Ltd. (VJTbio) is a biopharmaceutical company established in 2016, specializing in the research, development, production, and sale of innovative drugs for the animal health sector. The company was founded by Dr. Luo Haoshu, a reproductive endocrinology expert and researcher at the State Key Laboratory of Agrobiotechnology at China Agricultural University. Dr. Luo's academic background in reproductive diseases and gene-engineered drugs, combined with a desire to translate research into practical applications, led to the creation of VJTbio.
VJTbio focuses on developing advanced animal drugs, particularly recombinant protein and antibody therapeutics, often considered Class 1 new veterinary drugs in China. The company's product pipeline targets three main areas: animal reproduction, disease prevention and control, and pet diseases. Key products include a long-acting recombinant porcine follicle-stimulating hormone for synchronized breeding in livestock, cytokine products to prevent and treat diseases like porcine epidemic diarrhea virus (PEDV), and antibody drugs for conditions in cats and dogs such as tumors, autoimmune diseases, and pain. Many of its products are first-in-class globally and are protected by international PCT patents.
The company operates a comprehensive industrial chain, from initial R&D and clinical trials to large-scale production and sales. Its R&D headquarters are in Beijing, and it runs a GMP-certified production facility in Taizhou, Zhejiang, which is one of the largest and most advanced domestic plants for producing animal protein drugs via mammalian cell culture. VJTbio has received significant financial backing, completing a Series B funding round of over 100 million RMB in 2020 and a Series C round for several hundred million RMB in 2023, with investors including SDIC Capital and China Life Equity Investment.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES C✓Equity / VC | May 2023 | $28M | $220M | Capital Development Investment Fund · Xinshang Capital · FC Capital · Beijing Zhongguancun Science City Innovation Development | ↗ |
| SPINOUT✓Other financing | Jan 2016 | $0 | — | China Agricultural University | — |
Growth signals
Latest recorded traffic for Weijiexin Biological Technology is 660 monthly website visits, down 25% over the last three months.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Weijiexin Biological Technology in the Haidian ecosystem
The Weijiexin Biological Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later8 investors entered at this stage
- CFCapital Development Investment Fund
Xinshang Capital
FC Capital
Beijing Zhongguancun Science City Innovation Development- CIChina Life Private Equity Investment
SDIC Venture Capital
Shunde Science and Technology Group(Kecan Group)- SGShanghai STVC Group
Other known investors1 additional known investor
China Agricultural University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Weijiexin Biological Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Weijiexin Biological Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









